Document is current
Any future updates will be listed below
-
Authors
Zabala, Alexander http://orcid.org/0000-0001-5389-1271
Gottsäter, Anders
Lind, Marcus
Svensson, Ann-Marie
Eliasson, Björn
Bertilsson, Rebecka
Ekelund, Jan
Nyström, Thomas
Jonsson, Magnus
-
Funding
Funding for this research was provided by:
Hjärt-Lungfonden (20190298)
Stockholms Läns Landsting (20170120)
Skånes universitetssjukhus (430751)
Hulda och E Conrad Mossfelts Stiftelse för Vetenskaplig Forskning Inom Hjärt- och Kärlsjukdomarnas Område
Västra Götalandsregionen
Karolinska Institute
- License Information
-
More Information
Article History
Received: 10 February 2021
Accepted: 15 April 2021
First Online: 24 April 2021
Declarations
:
: All patients have consented to being reported in the Swedvasc and NDR. No individual consent is required for inclusion in this study, according to Swedish law. The study was approved by the ethics committee of the University of Lund, Sweden (2016/232 and 2016/544).
: Not applicable.
: TN has received unrestricted grants from AstraZeneca and NovoNordisk and has served on national advisory boards of Amgen, Novo Nordisk, Sanofi-Aventis, Eli Lilly, MSD and Boehringer Ingelheim. AG has served on national advisory boards of Amgen, Astra Zeneca, Bayer, Boehringer-Ingelheim, Bristol Myers Squibb, Gore, Leo Pharma, Novartis, Novo Nordisk, Pfizer, and Sanofi. BE reports personal fees from AMGEN, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, Mundipharma, Navamedic, NovoNordisk, RLS Global, and grants and personal fees from Aanofi, all outside the submitted work. ML has received research grants from DexCom and Novonordisk and been consultant for Astra Zeneca, Boheringer Ingelheim, DexCom, Eli Lilly, MSD and Novonordisk.
